CAH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cardinal Health Inc (CAH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock demonstrates strong financial performance, consistent analyst upgrades, and a bullish technical setup. Despite the absence of Intellectia Proprietary Trading Signals today, the overall sentiment and data suggest a favorable long-term investment opportunity.
The technical indicators for CAH are bullish. The MACD is positive and expanding, RSI is neutral at 64.046, and moving averages (SMA_5 > SMA_20 > SMA_200) confirm an upward trend. The stock is trading near its resistance level (R1: 228.357), suggesting potential for further upside. Key support is at 216.324.
Strong financial performance in Q2 2026, with revenue up 18.75% YoY, net income up 16.75% YoY, and EPS up 19.39% YoY.
Consistent analyst upgrades with increased price targets (ranging from $233 to $
and positive commentary on business strength.
Bullish technical indicators and upward momentum in stock price.
Post-market price decline of -0.15%, though minor, could indicate short-term profit-taking.
Lack of significant hedge fund or insider trading activity, suggesting neutral institutional sentiment.
Cardinal Health reported strong Q2 2026 financials: Revenue increased to $65.63 billion (up 18.75% YoY), net income rose to $467 million (up 16.75% YoY), EPS grew to 1.97 (up 19.39% YoY), and gross margin improved to 3.52% (up 3.83% YoY). These metrics highlight robust growth and operational efficiency.
Analysts are overwhelmingly positive on CAH, with multiple firms raising price targets recently. Barclays, Wells Fargo, Evercore ISI, UBS, and others have set price targets between $233 and $260, citing strong business performance, particularly in pharmaceutical and specialty segments, and consistent execution. The consensus rating is 'Buy' or 'Outperform'.
